Implantable defibrillators in the third millennium: increasingly relegated to a standby role?

In the last five years, evidence has accumulated confirming the superiority of implantable cardioverter-defibrillator (ICD) therapy compared to antiarrhythmic drug therapy for prevention of sudden death [(1,2)][1]. Clinical trials, with rare exception, have established mortality benefits of ICD